je.st
news
Tag: patients
Merck Announces Positive Study Investigating the Use of KEYTRUDA (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma
2014-11-16 10:25:00| Merck.com - Research & Development News
Dateline City: ZURICH KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress ZURICH--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival (PFS, as assessed by RECIST 1.1, independent central review) (HR 0.57 and 0.50 for 2 mg/kg and 10 mg/kg every three week doses, respectively), compared to chemotherapy (P<0.0001 for both comparisons) Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
study
positive
Hormel Provides Cancer Patients with Nutritional Offerings
2014-11-15 13:55:57| Food - Topix.net
The specialty foods division of Hormel Foods Corp., Austin, Minn., partnered with the Cancer Nutrition Consortium, West Palm Beach, Fla., to provide cancer patients with nutritional offerings for their specific individual needs during cancer treatment. The Cancer Nutrition Consortium is an innovative collaboration among some of the most notable cancer centers, chefs and nutritional experts focusing on nutritional concerns of patients undergoing cancer treatment.
Tags: cancer
patients
offerings
nutritional
Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Nave and Difficult-to-Cure Patients
2014-11-11 14:00:00| Merck.com - Research & Development News
Dateline City: BOSTON Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir (MK-5172/MK-8742, the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, respectively) with or without ribavirin (RBV) in treatment-nave and previously-treated (with peg-interferon/ribavirin [PR]) patients with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection -- the C-WORTHy study (Parts A and B). Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
study
treatment
phase
CDC buying more gear for hospitals treating Ebola patients
2014-11-08 03:33:16| Food - Topix.net
Production operators stand by tubes in a bioreactor as they prepare a cell culture for growing active Ebola vaccine substances in the laboratory of Bavarian Nordic A/S in Kvistgaard, Denmark. The vaccine, to combat the virus that has killed thousands in West Africa, combines a shot from Johnson & Johnson's Janssen unit in the Netherlands with one developed by Danish biotechnology company Bavarian Nordic, J&J said.
Tags: buying
gear
patients
hospitals
Ironwood Pharmaceuticals Initiates Phase III Trial Of 72 mcg Linaclotide In Adult Patients With Chronic Idiopathic Constipation
2014-11-05 05:57:43| drugdiscoveryonline Home Page
Ironwood Pharmaceuticals, Inc. announced recently the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC)
Sites : [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] next »